Insider transactions

TANG CAPITAL PARTNERS LP

CIK 1191935 · last filed 2024-09-18

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$15.31M
Companies
15
Total Filings
74
Lifetime Open-Market Net
$232.31M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

LJPC price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
4747 EXECUTIVE DRIVE
SUITE 210
SAN DIEGO, CA 92121
Phone
(858) 200-3830
State of Incorporation
DE
Related Filers
TANG CAPITAL MANAGEMENT LLC — 208 joint filings, latest 2025-02-27
Kevin Tang — 205 joint filings, latest 2025-02-27
LA JOLLA PHARMACEUTICAL CO — 54 joint filings, latest 2022-08-24
John G Lemkey — 29 joint filings, latest 2020-09-30
Michael S Hearne — 21 joint filings, latest 2022-08-24
ANAPTYSBIO, INC — 3 joint filings, latest 2024-02-14
Galena Biopharma, Inc. — 3 joint filings, latest 2012-02-14
bluebird bio, Inc. — 3 joint filings, latest 2024-02-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Singular Genomics Systems, Inc. (OMIC) Delisted 10%+ Owner 340,000 $20.01 $6.80M $5.42M 1 2024-09-18
RAIN 10%+ Owner 3,850,513 $0.53 $2.04M $3.69M 3 2023-12-18
TCR2 THERAPEUTICS INC. (TCRR) Delisted 10%+ Owner 4,299,852 $1.48 $6.36M $491.3K 1 2023-05-10
Jounce Therapeutics, Inc. (JNCE) Delisted 10%+ Owner 5,279,801 $1.88 $9.93M $257.9K 1 2023-03-14
LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted 10%+ Owner 9,849,224 $6.22 $61.26M $129.62M 11 2021-12-01
APVO 10%+ Owner 1 $1.50 $2 $23.94M 3 2021-11-26
Odonate Therapeutics, Inc. (ODT) Delisted 10%+ Owner 15,238,782 $1.12 $17.07M $16.61M 5 2020-09-30
HRTX 10%+ Owner 8,532,156 $0.30 $2.57M $33.28M 3 2018-04-02
Mirati Therapeutics, Inc. (MRTX) Delisted 10%+ Owner 1,238,543 $58.70 $72.70M $1.19M 2 2013-10-28
HERON THERAPEUTICS, INC. /DE/ (APPA) Delisted Director 528,767 — — $2.50M 3 2010-05-26
VNDA 10%+ Owner 2,715,852 $3.94 $10.70M -$3.42M 7 2010-01-19
PENWEST PHARMACEUTICALS CO (PPCO) Delisted 10%+ Owner 6,040,136 — — $12.95M 7 2009-03-10
NEOSE TECHNOLOGIES INC (NTEC) Delisted 10%+ Owner 0 $9.63 $0 $520.7K 8 2008-11-12
ARADIGM CORP (ARDM) Delisted 10%+ Owner 13,500 — — $51.2K 3 2008-10-23
Ardea Biosciences, Inc./DE (RDEA) Delisted 10%+ Owner 211,383 — — $5.22M 3 2008-05-16

Recent Filings · Page 2 of 8

74 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-11-06 APVO Buy (P) +4,310,025 $74.55M EDGAR
2020-09-30 Odonate Therapeutics, Inc. (ODT) Delisted Buy (P) +554,410 $7.28M EDGAR
2020-02-03 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Buy (P) +509,310 $3.44M EDGAR
2020-01-13 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Buy (P) +8,915,046 $52.30M EDGAR
2018-12-13 Odonate Therapeutics, Inc. (ODT) Delisted Buy (P) +100,000 $1.56M EDGAR
2018-10-01 Odonate Therapeutics, Inc. (ODT) Delisted Buy (P) +160,000 $3.07M EDGAR
2018-09-26 Odonate Therapeutics, Inc. (ODT) Delisted Buy (P) +160,000 $3.16M EDGAR
2018-04-02 HRTX Buy (P) +576,924 $15.00M EDGAR
2018-03-02 Odonate Therapeutics, Inc. (ODT) Delisted Buy (P) +56,200 $1.54M EDGAR
2018-02-27 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Buy (P) +450,000 $14.32M EDGAR
Showing 11–20 of 74
Page 2 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.